Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALPS GroupALPS -0.13%10 Equity-to-Asset is 0.00 as of Sep. 2025. GuruFocus rates ALPS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, ALPS Group ranks worse than 88.5% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ALPS Group's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $-0.03 Mil. ALPS Group's Total Assets for the quarter that ended in Sep. 2025 was $0.00 Mil.
The historical rank and industry rank for ALPS Group's Equity-to-Asset or its related term are showing as below:
ALPS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.23 Max: 0.35
Current: -0.13
During the past 3 years, the highest Equity to Asset Ratio of ALPS Group was 0.35. The lowest was -0.13. And the median was 0.23.
ALPS's Equity-to-Asset is ranked worse than 88.5% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs ALPS: -0.13
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ALPS Group Equity-to-Asset Related Terms
ALPS Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for ALPS Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group Equity-to-Asset Chart
ALPS Group Annual Data
Trend
Mar23
Mar24
Mar25
Equity-to-Asset
0.35
0.23
-0.13
ALPS Group Semi-Annual Data
Mar23
Mar24
Sep24
Mar25
Sep25
Equity-to-Asset
0.35
0.23
0.00
-0.13
0.00
ALPS vs OKYO, CGTX, INO: Equity-to-Asset Comparison
For the Biotechnology subindustry, ALPS Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALPS Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALPS Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ALPS Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ALPS Group's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group (ALPS) has a Equity-to-Asset of 0.00 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ALPS Group and its competitors. According to the industry distribution chart, ALPS Group ranks #1254 out of 1417 companies in the Biotechnology industry, placing it in the top 88.5%.
Is ALPS Group's Equity-to-Asset too high?
ALPS Group's current Equity-to-Asset is 0.00. Based on the distribution chart, ALPS Group ranks #1254 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ALPS Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ALPS Group's Equity-to-Asset compare to OKYO and CGTX?
According to the Biotechnology industry distribution chart, ALPS Group ranks #1254 out of 1417 companies for Equity-to-Asset. This places ALPS Group in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ALPS Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALPS Group's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALPS Group stock overvalued right now?
ALPS Group (ALPS) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. ALPS Group's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ALPS Group (ALPS), the current Equity-to-Asset is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
10GF Score
Get the complete analysis for ALPS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPS has been successfully added to your 
